Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Pulse Biosciences, Inc.NASDAQ: PLSE
Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026
Other non-cash items dips below year-ago levels
Q2 FY2026 other non-cash items of $329K fell 40.8% year over year, behind the +99.1% change in trailing-twelve-month other non-cash items. Sequentially, it fell 49.5% from the prior quarter. Over 3 fiscal years it compounded at -48.9% a year.
Context
- Other non-cash items amounted to 329.4% of revenue in FY2025.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -40.8% toward the trailing-twelve-month pace of +99.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 1.15M USD
- Year-over-year change
- +19116.7%
- 4-year CAGR
- +206.9%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15M | +19116.7% |
| FY2024 | 2024-12-31 | 6K | -53.8% |
| FY2023 | 2023-12-31 | 13K | -99.8% |
| FY2022 | 2022-12-31 | 8.66M | +66530.8% |
| FY2021 | 2021-12-31 | 13K | — |
Other Non-Cash Items vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +99.1% is the 7th highest of 11, against a peer median of +119.6%.
- Other non-cash items amounts to 133.1% of revenue for PLSE, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $537.44M USD | +2070.5% | +301.9% | 12015.3% | |
| LTM Mar 2026 | €26.46M EUR | +259.2% | — | 70.9% | |
| LTM Mar 2026 | $20.61M USD | +198.6% | — | 3.1% | |
| LTM Apr 2026 | $20.34M USD | +239.8% | +125.9% | 7.0% | |
| LTM Jun 2026 | $10.32M USD | +25.1% | +122.4% | 542.1% | |
| LTM Jan 2026 | $9.95M USD | +137.6% | — | 11.9% | |
| LTM Jun 2026 | $8.8M USD | -86.9% | +18.5% | 16.1% | |
| LTM Mar 2026 | $4.94M USD | -354.4% | — | 2.3% | |
| LTM Mar 2026 | $3.77M USD | +101.6% | -80.8% | 0.6% | |
| LTM Jun 2026 | $1.58M USD | +99.1% | -48.9% | 133.1% | |
| LTM Mar 2026 | $463K USD | -97.8% | — | 0.4% | |
| Peer median (excluding PLSE) | — | +119.6% | +122.4% | 9.4% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.66M) | (58.51M) | (42.21M) | (53.59M) | (72.78M) |
| Depreciation & Amortization | 1.15M | 1.36M | 1.21M | 1.18M | 1.07M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.6M | 5.19M | 7.18M | 13.59M | 21.46M |
| Change in Working Capital | (6.2M) | (3.72M) | 768K | 2.47M | (5.02M) |
| Accounts Receivables | (61K) | 20K | 109K | 48K | (274K) |
| Inventory | (5.82M) | (2.65M) | 0 | 0 | (136K) |
| Accounts Payables | 1.16M | (1.3M) | 263K | (201K) | 1.13M |
| Other Working Capital | (1.47M) | 221K | 396K | 2.63M | (5.74M) |
| Other Non-Cash Items | 13K | 8.66M | 13K | 6K | 1.15M |
| Operating Cash Flow | (54.1M) | (47.01M) | (33.04M) | (36.34M) | (54.12M) |
| Capital Expenditures | (437K) | (401K) | (121K) | (125K) | (315K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (20K) |
| Investing Cash Flow | 7.56M | (401K) | (121K) | (125K) | (335K) |
| Debt Repayment | 407K | 65M | 0 | 0 | 0 |
| Common Stock Issued | 56.7M | 14.86M | 16.39M | 59.65M | 17.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.51M | 75K | (6K) | 50.49M | 0 |
| Financing Cash Flow | 62.69M | 79.94M | 16.39M | 110.14M | 17.15M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.15M | 32.53M | (16.77M) | 73.67M | (37.3M) |
| Free Cash Flow | (54.53M) | (47.41M) | (33.16M) | (36.47M) | (54.44M) |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.